March 26, 2020 / 12:21 PM / 6 days ago

BRIEF-Intercept Pharmaceuticals Provides Regulatory And Business Update

March 26 (Reuters) - Intercept Pharmaceuticals Inc:

* INTERCEPT PHARMACEUTICALS PROVIDES REGULATORY AND BUSINESS UPDATE

* INTERCEPT PHARMACEUTICALS- AMID COVID-19 FDA NOTIFIED IT HAS RESCHEDULED PREVIOUSLY ANNOUNCED ADCOM RELATED NDA FOR OBETICHOLIC ACID IN LIVER FIBROSIS

* INTERCEPT PHARMACEUTICALS INC - PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE FOR NDA REMAINS JUNE 26, 2020

* INTERCEPT PHARMACEUTICALS INC - RECONFIRMING OUR PREVIOUSLY ANNOUNCED NON-GAAP ADJUSTED OPERATING EXPENSES GUIDANCE FOR FULL YEAR 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below